RxDoctor Payments Data

Bryan Burns, DO

Internal Medicine · Saint Louis, MONPI 1588874366

Payments from drug & device makers

$821in general payments, 2019–2025

Across 45 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$331
  • Novo Nordisk$134
  • Lilly USA, LLC$120
  • Pfizer$85
  • Abbott$39
  • AstraZeneca$33
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$821100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$821 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$89,152
Medicare patients
282
Services billed
2,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$159,602
MounjaroTirzepatide67$79,995
JanuviaSitagliptin Phosphate54$68,035
Trelegy ElliptaFluticasone/Umeclidin/Vilanter92$62,044
Dabigatran EtexilateDabigatran Etexilate Mesylate113$50,081
TrulicityDulaglutide35$46,112
Semglee (Yfgn)Insulin Glargine-Yfgn54$38,714
ProliaDenosumab20$34,252
JardianceEmpagliflozin31$29,176
OzempicSemaglutide25$27,412
XareltoRivaroxaban21$25,487
MyrbetriqMirabegron32$19,088
Atorvastatin Calcium1,200$13,673
Semglee (Yfgn) PenInsulin Glargine-Yfgn21$13,121
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$12,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$85$166,781225 claims
Lilly USA, LLCMounjaro, Trulicity$120$126,107102 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$18$79,991139 claims
Novo NordiskOzempic$134$27,41225 claims
AbbVieCreon$331$6,03313 claims
AstraZenecaSymbicort$33$4,85715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →